JJ
RAPP

Johnson & Johnson’s Rapport Therapeutics RAPP Stock Holding History

Johnson & Johnson’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.8M Hold
1,784,517
– – 8.56% 4
2025
Q4 		$54.1M Hold
1,784,517
– – 9.75% 3
2025
Q3 		$53M Sell
1,784,517
-713,534
-29% -$12.7M 10.52% 4
2025
Q2 		$28.6M Hold
2,498,051
– – 8.55% 3
2025
Q1 		$25.1M Hold
2,498,051
– – 7.33% 5
2024
Q4 		$44.3M Hold
2,498,051
– – 11.48% 3
2024
Q3 		$51.2M Hold
2,498,051
– – 11.97% 2
2024
Q2 		$58.1M Buy
+2,498,051
New +$57.8M 14.5% 2

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Johnson & Johnson's RAPP Position: Q1 2026 in Review

Johnson & Johnson held its Rapport Therapeutics (RAPP) position steady in Q1 2026 at 1,784,517 shares worth $55.8M. The position accounts for 8.56% of the portfolio, ranked #4.

Johnson & Johnson first reported a position in RAPP in Q2 2024 and has held it in 8 quarters since. The position peaked at $58.1M in Q2 2024. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Johnson & Johnson held 1,784,517 shares of Rapport Therapeutics worth $55.8M as of Q1 2026.
  • Johnson & Johnson left its Rapport Therapeutics share count unchanged in Q1 2026.
  • Rapport Therapeutics made up 8.56% of Johnson & Johnson's portfolio in Q1 2026, its #4 holding.
  • Johnson & Johnson first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Johnson & Johnson's Rapport Therapeutics position peaked at $58.1M in Q2 2024.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Johnson & Johnson's 13F filing for Q1 2026, filed 13 May 2026.